A randomised, double-blind, parallel-group, multicentre study to demonstrate improvement in symptoms of constipation in subjects with non-malignant pain taking oxycodone equivalent of greater than 20 mg/day and less than 50 mg/day as oxycodone/naloxone prolonged release compared to subjects taking oxycodone prolonged release tablets alone.

Trial Profile

A randomised, double-blind, parallel-group, multicentre study to demonstrate improvement in symptoms of constipation in subjects with non-malignant pain taking oxycodone equivalent of greater than 20 mg/day and less than 50 mg/day as oxycodone/naloxone prolonged release compared to subjects taking oxycodone prolonged release tablets alone.

Completed
Phase of Trial: Phase III

Latest Information Update: 01 Dec 2014

At a glance

  • Drugs Oxycodone; Oxycodone/naloxone
  • Indications Pain
  • Focus Adverse reactions
  • Sponsors Mundipharma GmbH
  • Most Recent Events

    • 02 Sep 2010 Results were presented at the 13th World Congress on Pain.
    • 16 Oct 2008 Status changed from active, no longer recruiting to completed.
    • 19 Oct 2007 Status changed from recruiting to in progress.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top